Markets
markets

Trump admin is working to cut pharma ads: Report

The Trump administration is drafting a policy that would “make it harder and more expensive” for drugmakers to advertise directly to consumers, Bloomberg News reported on Tuesday.

The policy being floated is not an outright ban but one that adds “legal and financial hurdles,” sources told Bloomberg. Pharmaceutical companies account for a huge chunk of the advertising industry.

The news sent some pharma stock nudging down, including Novo Nordisk and Eli Lilly, which currently sell wildly popular GLP-1 weight-loss drugs. Its unclear how the policy would affect telehealth companies like Hims & Hers, which also advertise drugs to consumers but operate in a legal gray area.

The news sent some pharma stock nudging down, including Novo Nordisk and Eli Lilly, which currently sell wildly popular GLP-1 weight-loss drugs. Its unclear how the policy would affect telehealth companies like Hims & Hers, which also advertise drugs to consumers but operate in a legal gray area.

More Markets

See all Markets
markets

JPMorgan recommends bullish options bet on Nvidia ahead of earnings

Nvidia, the most valuable stock in the world, has lagged its semiconductor peers over the past three months in the run-up to its fiscal 2026 third-quarter results, due out after Wednesday’s close.

JPMorgan reckons an earnings beat, as well as signs that the company and its suppliers are well positioned to meet the ever-growing demand for its AI offerings, would be sufficient catalysts to unlock a catch-up trade that sends shares soaring back toward all-time highs.

“We favor owning call spreads as a strong beat-and-raise from NVDA and positive commentary around supply could clear recent sector underperformance and could propel NVDA above its average historical move,” wrote Bram Kaplan, head of America equity derivatives strategy at JPM.

The recommendation:

  • Buy calls at a strike price of $197.50 for this Friday’s expiry; and

  • Sell the same amount of calls at a strike price of $207.50 for the same expiry.

The options-implied move is plus or minus ~6.4%. To break even on this position (by the time of expiry, based on current prices), you’d need to see shares up above $199.30.

The chip designer has traded between ~$180 and $210 since the end of September. So, the upper strike on this call spread caps the upside a little below the stock’s October 29 intraday peak of $212.19.

The max gain would be roughly 550% of the premium paid; the max loss, of course, would be 100%.

markets

Bitcoin’s having its worst month since 2022 as the sell-off continues, with BTC dipping below $90,000

Bitcoin slid below $90,000 on Monday night for the first time since April, extending a month-long rout that has now erased all of its 2025 gains. The world’s largest cryptocurrency briefly hit $89,350, its lowest level since February, before rebounding slightly to hover near $91,000. Six weeks ago, prices had hit a record $126,250.

The slide comes as risk appetite evaporates across markets, with speculative tech stocks tumbling and hedge funds de-risking — while some investors use bitcoins losses for year-end tax loss harvesting.

bitcoin
(Sherwood Media)

As a result, bitcoin is now suffering its worst one-month stretch since the deep 2022 sell-off, and its worst Q4 since 2018 — despite November typically being its strongest month. With fear gauges hitting extreme levels, some traders are now positioning for a potential slide toward $86,000 to $88,000.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.